Price (delayed)
$4
Market cap
$26.65M
P/E Ratio
1.35
Dividend/share
N/A
EPS
$2.97
Enterprise value
$33.5M
MEI Pharma, Inc. is a late-stage pharmaceutical company focused on developing potential new therapies for cancer. MEI Pharma's portfolio of drug candidates contains four clinical-stage assets, including zandelisib, currently in
There are no recent dividends present for MEIP.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.